Details of the Drug Reposition

General Information of This Drug (ID: DMWXLYZ)

Drug Name
Darifenacin   DMWXLYZ
Synonyms
Enablex; Emselex; 133099-04-4; UNII-APG9819VLM; UK-88525; APG9819VLM; CHEMBL1346; CHEBI:391960; (S)-1-(2-(2,3-Dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide; 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide; darifenacine; [3H]darifenacin; 2-{(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-diphenylacetamide; NCGC00168775-01; Darifenacin (USAN/INN); Darifenacinum; Darifenacina; Darifenacin [USAN:INN:BAN]; Emselex; Emselex (TN); Enablex (TN)
Therapeutic Class
Urinary antispasmodics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Overactive bladder DISQR5TD GC50.0 Discontinued in Phase 2 [1]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Priapism DISX1G4Y N.A. Investigative [2]
------------------------------------------------------------------------------------

References

1 Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma
2 Darifenacin FDA Label